

#19

Patent  
030639.0044.CPA1



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Bradford J. Duft, *et al.*

Serial No.: 09/445,517

Filed: December 6, 1999

For: *METHODS FOR TREATING OBESITY*

TECH CENTER 1600/2303  
SEP - 7 2004

Group Art Unit: 1645

Examiner: S. Devi

SEP - 7 2004

900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In compliance with the Applicants' duty under 37 CFR 1.56, the following information is brought to the attention of the Examiner. The items are listed on the attached Form PTO/SB/08A and copies are enclosed for the convenience of the Examiner. Applicants respectfully request that these documents be made of record in the above-referenced application.

The item identified in this Supplemental Information Disclosure Statement may or may not be "material" pursuant to 37 CFR 1.56 and the submission thereof by Applicants shall not be

CERTIFICATE OF MAILING  
(37 CFR §1.8 a)

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

April 10, 2002  
Date of Deposit

BARBARA J. KIELT  
Name of Person Mailing Paper  
Barbara J. Kielt  
Signature of Person Mailing Paper

construed as an admission that any such patent, publication or other information referred to therein is material or considered to be material (37 CFR 1.97(h)), or even qualifies as "prior art" under 35 U.S.C. § 102 with respect to this invention unless specifically designated by Applicants as such.

The filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information, as defined in 37 CFR 1.56, exists.

This Supplemental Information Disclosure Statement is being submitted under 37 CFR 1.97(c) (2). Enclosed is a check in the amount of \$180.00 to cover the fee pursuant to 37 CFR 1.17(p). The Commissioner is authorized to charge any additional fee required by this submission or to credit any over payment to counsel's Deposit Account No. 50-1273.

Respectfully submitted,

Dated: 4/09/02

By: Lisa M. McGeehan  
Lisa M. McGeehan  
Reg. No. 41185

BROBECK, PHLEGER & HARRISON LLP  
12390 El Camino Real  
San Diego, CA 92130-2081  
Phone (858) 720-2500  
Fax (858) 720-2555

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Complete if Known

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	09/445,517
Filing Date	December 6, 1999
First Named Inventor	Bradford J. Duft
Group Art Unit	1645
Examiner Name	Devi, S.
Attorney Docket Number	

Sheet

of

NON PATENT LITERATURE DOCUMENTS

Examiner Initials <sup>1</sup>	Cite No. <sup>2</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>3</sup>
		KOLTERMAN et al., "Effect Of 14 Days' Subcutaneous Administration Of The Human Amylin Analogue, Pramlintide (AC137) On An Intravenous Insulin Challenge And Response To A Standard Liquid Meal In Patients With IDDM," <u>Diabetologia</u> , 39(4):492-9 (1996)	
		KONG et al., "Infusion Of Pramlintide, A Human Amylin Analogue, Delays Gastric Emptying In Men With IDDM," <u>Diabetologia</u> , 40(1):82-88 (1997)	
		KONG et al., "The Effect Of Single Doses Of Pramlintide On Gastric Emptying Of Two Meals In Men With IDDM," <u>Diabetologia</u> , 41(5):577-83 (1998)	
		NYHOLM et al., "Acute Effects Of The Human Amylin Analog AC137 On Basal And Insulin-Stimulated Euglycemic And Hypoglycemic Fuel Metabolism In Patients With Insulin-Dependent Diabetes Mellitus," <u>J. Clin. Endocrinol. Metab.</u> , 81(3):1083-89 (1996)	
		SCHMITZ et al., "Effects Of Amylin And The Amylin Agonist Pramlintide On Glucose Metabolism," <u>Diabetic Med.</u> , 14(2):S19-S23 (1997)	
		THOMPSON et al., "Effects Of 4 Weeks' Administration Of Pramlintide, A Human Amylin Analogue, On Glycaemia Control In Patients With IDDM: Effects On Plasma Glucose Profiles And Serum Fructosamine Concentrations," <u>Diabetologia</u> , 40(11):1278-1285 (1997)	
		THOMPSON et al., "Pramlintide: A Human Amylin Analogue Reduced Postprandial Plasma Glucose, Insulin, And C-Peptide Concentrations In Patients With Type 2 Diabetes," <u>Diabetic Med.</u> , 14(7):547-55 (1997)	
		WANG et al., "Influence Of Islet Amyloid Polypeptide And The 8-37 Fragment of Islet Amyloid Polypeptide on Insulin Release From Perfused Rat Islets," <u>Diabetes</u> , 42(2):330-5 (1993)	

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.